Catalent & BASF Form Bioavailability Alliance

The companies will combine their expertise to provide a range of services to address pipeline challenges with BCS Class II and IV poorly bioavailable compounds.

Catalent Pharma Solutions and BASF have signed a collaboration deal to provide solutions for bioavailability challenges of new molecular entities with solubility or permeability issues.

The companies will combine their expertise to provide a range of services to address pipeline challenges with BCS Class II and IV poorly bioavailable compounds.

The alliance will provide services include: feasibility studies across multiple technologies, solid state chemistry, consulting and training, expert formulation services, excipients and optimal dose form development, to scale-up and supply.

"We are glad to bring our in depth knowledge of polymeric excipients, includi